Previous 10 | Next 10 |
2023-09-12 15:49:54 ET More on Biogen Seeking Alpha’s Quant Rating on Biogen Historical earnings data for Biogen Financial information for Biogen Biogen Inc. ( BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Stoc...
2023-09-12 13:26:27 ET More on Reata Pharmaceuticals Seeking Alpha’s Quant Rating on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward San...
2023-09-11 14:47:09 ET Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 10:40 AM ET Company Participants Christopher Viehbacher - CEO Conference Call Participants Terence Flynn - Morgan Stanley Presentation ...
2023-09-11 12:04:11 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Financial information for Novartis Novartis: Q2 Beats Expectations, But Still Pricey ...
2023-09-11 08:19:33 ET Summary Amylyx Pharmaceuticals is a small biotech company focused on developing therapies for neurodegenerative diseases. Their FDA-approved product, Relyvrio, is used to treat amyotrophic lateral sclerosis, a fatal neurodegenerative disorder. AMLX stock...
2023-09-11 07:19:20 ET Summary This article provides a follow-up study reviewing the 6-month performance of the top "zombie" firm portfolio selections based on Federal Reserve metrics. Three different model returns from March are reviewed, with sample stock portfolios down -23.4%,...
2023-09-10 15:17:31 ET HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its “buy” ratings list. IQVIA ( NYSE: IQV ) and Zoetis ( NYSE: ZTS ) were labeled “quality growthȁ...
2023-09-09 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-09-09 07:45:00 ET As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. When all's said and done, the move w...
2023-09-08 15:00:57 ET More on the markets The Unemployment Rate Just Signaled That A Recession May Occur Within The Next 6 Months High Yield Signal Does Not Align With Bearish Outlook For SPY SPY: The Calm Before The Storm Bulls vs. Bears: SA analysts weigh ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...